Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells
about
VEGF stimulates RCAN1.4 expression in endothelial cells via a pathway requiring Ca2+/calcineurin and protein kinase C-deltaCysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cellsDown's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1Down syndrome candidate region 1-like 1 (DSCR1-L1) mimics the inhibitory effects of DSCR1 on calcineurin signaling in endothelial cells and inhibits angiogenesisRisk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysisArterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumabLung stem cell differentiation in mice directed by endothelial cells via a BMP4-NFATc1-thrombospondin-1 axisModulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivoNFATc1 regulates lymphatic endothelial developmentThe vertebrate RCAN gene family: novel insights into evolution, structure and regulationVEGFA-VEGFR2 Signaling PathwayNF-kappaB-inducing kinase phosphorylates and blocks the degradation of Down syndrome candidate region 1.Gene expression in periodontal tissues following treatment.Identification of signaling systems in proliferating and involuting phase infantile hemangiomas by genome-wide transcriptional profilingSnake venom VEGF Vammin induces a highly efficient angiogenic response in skeletal muscle via VEGFR-2/NRP specific signalingIdentification of a peptide fragment of DSCR1 that competitively inhibits calcineurin activity in vitro and in vivo.Signaling mechanisms in infantile hemangiomaKaposi's sarcoma herpesvirus K15 protein contributes to virus-induced angiogenesis by recruiting PLCĪ³1 and activating NFAT1-dependent RCAN1 expression.Cyclosporin A promotes tumor angiogenesis in a calcineurin-independent manner by increasing mitochondrial reactive oxygen species.Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab.Cancer therapy and cardiovascular risk: focus on bevacizumab.Vascular endothelial growth factor induces MEF2C and MEF2-dependent activity in endothelial cells.Tight control - decision-making during T cell-vascular endothelial cell interaction.CD31 signals confer immune privilege to the vascular endothelium.NFAT as cancer target: mission possible?Creation and characterization of BAC-transgenic mice with physiological overexpression of epitope-tagged RCAN1 (DSCR1)Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis.Signals and genes induced by angiogenic growth factors in comparison to inflammatory cytokines in endothelial cells.Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangiomaRisk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review.Inflammatory angiogenesis in atherogenesis--a double-edged sword.Prokineticin 1 modulates IL-8 expression via the calcineurin/NFAT signaling pathwayThe Down syndrome critical region gene 1 short variant promoters direct vascular bed-specific gene expression during inflammation in miceMetastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenibDown's syndrome: protection against cancer and the therapeutic potential of DSCR1.Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.VEGF non-angiogenic functions in adult organ homeostasis: therapeutic implications.The role of transcription enhancer factors in cardiovascular biology.NFAT gene family in inflammation and cancer.Calcineurin-NFAT activation and DSCR-1 auto-inhibitory loop: how is homoeostasis regulated?
P2860
Q21136325-7E2DD530-32D2-4EFD-B72D-748738796367Q24546541-783975A7-66AF-47B4-B2CE-7B114C279DADQ24654657-75644D31-0356-47AB-A140-6406FD66EA84Q24680331-4B3634DD-FBA5-4200-AA2C-B838D2947E54Q27026453-1E7F42B0-8653-4DF1-A3A4-06F9269CF5FDQ28219257-9B2CAC2C-FD18-4CE0-AD1E-E74F730539F4Q28307071-098AA676-BC72-4911-A73F-50F4D453101BQ28505205-37C0B9E1-8202-4808-8995-2C1549D5DECDQ28593523-2B607EE4-02D0-426B-BF6A-ED3E3A074B49Q28660477-39B0A348-FED5-4298-BACA-983A8246EF10Q30225525-0BFD6B77-BE39-4B19-B3D5-C7DC7B83B4DBQ33308479-FEA77D85-F1A3-4497-8AC1-9B51AB598D19Q33349622-DBB6156A-D024-4E56-826D-646DA9C3DA79Q33427340-714574F9-C153-43BD-980E-10E6D8ADA5ADQ33911723-F56B789D-7D8C-4A14-9B07-15DAE66B12A3Q33947920-E73F8330-0871-43F1-8306-E01D650FE0C6Q33954701-33475792-3294-4F66-97DD-B932EBBE09ECQ34426472-CF956732-D234-4111-90ED-F3885B518A32Q34518356-A92662C6-DE50-4228-BE9A-D9BA6D8AFCDDQ34627103-819F16A6-AB3F-4CF6-B9DD-B4E6CE653239Q35703835-F67914FF-E4B0-4EA3-9926-668703AD7D4AQ35900356-8A8BA6CC-F00F-45EB-812F-09889A1BAFE2Q36189812-0E019490-F43A-49B5-8238-D64EAA259799Q36238486-91BC85A2-F11A-4020-B503-24FF83B4B2C5Q36455193-66D01F6B-6870-4DA3-8486-E11918F61230Q36581939-EC1BCAA5-3B58-41DF-B27B-111255D1C642Q36868721-B8F11490-2DF5-4060-892C-CAC6C3AE7122Q36886847-E6402E42-AF7E-4882-9191-6DBCF96486FFQ36995485-C6F5A73D-FB09-4E87-BC50-72DE0E1A33C9Q37042424-6E01C717-C434-4AA3-AF73-5F000B91F37FQ37209762-783BA003-B0A0-429D-BFE1-8044F2FA61D9Q37254801-9DE1DA21-C8F2-4D96-93A7-A2B784B203C7Q37286605-43F923B1-19AB-4678-B5F9-9BF527162299Q37376498-C7116F39-4195-47B9-9ABF-23EF7D17C319Q37620385-8A11F621-5B1D-40DB-AC57-06C0BE6CA401Q37692420-F33ADFE0-3F64-4F27-9123-18AF323B362BQ37848687-4E500001-61FD-47D5-9537-DA2623CF2BEEQ38002167-CF098682-0B20-4218-9280-648B12F79A64Q38040813-4447CA32-792E-40EB-A741-9429016720F4Q38186014-174D9B8D-3001-4469-BD9A-C4CAB984F2C0
P2860
Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells
description
2004 nĆ® lÅ«n-bĆ»n
@nan
2004 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« Õ
ÕøÖÕ¬Õ«Õ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2004 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ°ÕøÖÕ¬Õ«Õ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2004幓ć®č«ę
@ja
2004幓č«ę
@yue
2004幓č«ę
@zh-hant
2004幓č«ę
@zh-hk
2004幓č«ę
@zh-mo
2004幓č«ę
@zh-tw
2004幓č®ŗę
@wuu
name
Down syndrome critical region ...... on activated endothelial cells
@ast
Down syndrome critical region ...... on activated endothelial cells
@en
Down syndrome critical region ...... on activated endothelial cells
@nl
type
label
Down syndrome critical region ...... on activated endothelial cells
@ast
Down syndrome critical region ...... on activated endothelial cells
@en
Down syndrome critical region ...... on activated endothelial cells
@nl
prefLabel
Down syndrome critical region ...... on activated endothelial cells
@ast
Down syndrome critical region ...... on activated endothelial cells
@en
Down syndrome critical region ...... on activated endothelial cells
@nl
P2093
P3181
P1433
P1476
Down syndrome critical region ...... on activated endothelial cells
@en
P2093
Boris A Hesser
David A Lewin
Gieri Camenisch
Hans-Peter Gerber
Napoleone Ferrara
Richard Scheller
Xiao Huan Liang
P304
P3181
P356
10.1182/BLOOD-2004-01-0273
P407
P577
2004-07-01T00:00:00Z